Related Experiment Video

Updated: Jun 10, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells

Alice M Walker1, Jacqueline J Stevens, Kenneth Ndebele

  • 1Molecular Toxicology Research Laboratory, NIH RCMI-Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, Jackson, MS 39217, USA. alice.m.walker@jsums.edu

International Journal of Environmental Research and Public Health
|July 17, 2010
PubMed

Insights

Arsenic trioxide demonstrated a dose-related cytotoxic effect on lung cancer cells, modulating apoptosis via caspase 3 and p38 MAPK activation. However, it did not induce significant cell cycle arrest.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Arsenic trioxide (Trisenox) is a treatment for acute promyelocytic leukemia (APL), known to inhibit cancer cell growth.
  • The precise mechanisms of arsenic trioxide-induced apoptosis involve complex signaling pathways, including cell-cycle progression and apoptosis.
  • Understanding these mechanisms is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To investigate the effects of arsenic trioxide on DNA synthesis in lung cancer cells (A549).
  • To determine if arsenic trioxide-induced apoptosis is mediated by caspase activation, p38 mitogen-activated protein kinase (MAPK) activation, and cell cycle arrest.

Main Methods:

  • A549 lung cancer cells were treated with varying concentrations of arsenic trioxide (0-10 microg/mL) for 48 hours.
  • DNA synthesis was measured using the [3H]thymidine incorporation assay.
  • Apoptosis was assessed via caspase-3 FITC assay, p38 MAPK activity by immunoblot assay, and cell cycle distribution by propidium iodide staining.

Main Results:

  • A dose-dependent cytotoxic effect was observed at higher arsenic trioxide concentrations, as indicated by reduced [3H]thymidine incorporation.
  • Arsenic trioxide treatment led to modulation of caspase-3 activity and activation of p38 MAPK in A549 cells.
  • No statistically significant differences in cell cycle distribution, specifically at the subG1 checkpoint, were found between control and treated cells.

Conclusions:

  • Arsenic trioxide exhibits cytotoxic effects on A549 lung cancer cells, partly through the induction of apoptosis mediated by caspase-3 and p38 MAPK.
  • The study suggests that arsenic trioxide-induced apoptosis in this model does not primarily rely on cell cycle arrest.
  • Further research is warranted to fully elucidate the complex apoptotic pathways influenced by arsenic trioxide in various cancer types.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...